Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

While Wall Street analysts maintain an optimistic average brokerage recommendation (ABR) of 1.53 (Strong Buy/Buy equivalent) for Boston Scientific with 21 Strong Buy ratings out of 30 recommendations, the article cautions investors to look beyond analyst sentiment. The Zacks Rank system assigns BSX a #5 (Strong Sell) rating due to a 0.3% decline in consensus earnings estimates over the past month to $3.29, suggesting analysts' growing pessimism about the company's earnings prospects. The article emphasizes that brokerage recommendations often have positive bias due to vested interests, while earnings estimate revisions are a more reliable predictor of near-term stock price movements.